Ignite Creation Date:
2024-05-06 @ 12:43 AM
Last Modification Date:
2024-10-26 @ 10:54 AM
Study NCT ID:
NCT01647425
Status:
COMPLETED
Last Update Posted:
2018-01-24
First Post:
2012-07-19
Brief Title:
Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer
Sponsor:
Centre Oscar Lambret
Organization:
Centre Oscar Lambret
Study Overview
Official Title:
Prevalence and Risk Factors for Persistent Tobacco or Alcohol Use Over the First Year of a First Lung or Head and Neck Cancer
Status:
COMPLETED
Status Verified Date:
2014-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ALTAK
Brief Summary:
This is an multicenter study for preventive and therapeutic strategies for patients with head and neck cancer
Detailed Description:
Continuing the chronic intoxication by either tobacco or alcohol after the initial diagnosis of a first lung or head and neck cancer significantly improves the risk of experiencing a second cancer and largely affects the long term survival Addiction intervention programs should be personalized according to the patients profile with the aim to develop more sustained intervention and monitoring in patients identified at higher risk of not spontaneously stopping harmful substance use As of today the trajectories of smoking and drinking habits and the risk factors for persisting smoking or drinking habits have been insufficiently explored among patients with a first lung or head and neck cancer
The ALTAK study aims to depict the rate of tobacco smokers 12 months after the initial diagnosis of a first lung or head and neck cancer The secondary objectives of the study are
to depict the rate of alcohol users 12 months after the initial diagnosis of a HN cancer
to depict the rate of tobacco smokers at cancer diagnosis
to depict the rate of alcohol users at cancer diagnosis
to determine the social motivational psychiatric tobacco-related alcohol-related and cannabis-related features associated with stopping tobacco in the year following the diagnosis of a first TARC
to determine the social psychiatric tobacco-related alcohol-related and cannabis-related features associated with stopping alcohol drinking in the year following the diagnosis of a first HN cancer
The ALTAK study aims to depict the rate of tobacco smokers 12 months after the initial diagnosis of a first lung or head and neck cancer The secondary objectives of the study are
to depict the rate of alcohol users 12 months after the initial diagnosis of a HN cancer
to depict the rate of tobacco smokers at cancer diagnosis
to depict the rate of alcohol users at cancer diagnosis
to determine the social motivational psychiatric tobacco-related alcohol-related and cannabis-related features associated with stopping tobacco in the year following the diagnosis of a first TARC
to determine the social psychiatric tobacco-related alcohol-related and cannabis-related features associated with stopping alcohol drinking in the year following the diagnosis of a first HN cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None